Skip to main content
SpringerLink
Log in

The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells

  • Brief Communication
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Purpose

Histone deacetylase inhibitors (HDACis) are a promising class of anticancer agents for the treatment of brain tumors. HDACis can increase the expression of brain-derived neurotrophic factor (BDNF) in brain cells. We have previously shown that BDNF reduces the viability of medulloblastoma cells. The aim of the present study was to examine the effect of the HDACi sodium butyrate (NaB) combined with human recombinant BDNF (hrBDNF), on the viability of human medulloblastoma cell lines.

Methods

DAOY and ONS76 medulloblastoma cells were treated with NaB, hrBDNF, or NaB combined with hrBDNF. Cell viability was measured with the MTT assay.

Results

NaB combined with hrBDNF significantly reduced the viability of DAOY medulloblastoma cells. In ONS76 cells, NaB alone reduced viability, but the effect was not potentiated by hrBDNF.

Conclusion

These findings provide early evidence for a rationale supporting further evaluation of HDACis and BDNF as a new combinatorial approach to inhibit the growth of medulloblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784

    Article  PubMed  CAS  Google Scholar 

  2. Lindsey JC, Anderton JA, Lusher ME, Clifford SC (2005) Epigenetic events in medulloblastoma development. Neurosurg Focus 19:E10

    Article  PubMed  Google Scholar 

  3. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912–1922

    Article  PubMed  CAS  Google Scholar 

  4. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755–766

    PubMed  CAS  Google Scholar 

  5. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787–1794

    Article  PubMed  CAS  Google Scholar 

  6. Kumar KS, Sonnemann J, Hong le TT, Buurman C, Adler F, Maass M, Völker U, Beck JF (2007) Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 27:465–470

    PubMed  CAS  Google Scholar 

  7. Spiller SE, Ditzler SH, Pullar BJ, Olson JM (2008) Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87:133–141

    Article  PubMed  CAS  Google Scholar 

  8. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM, Zhang W, Lu RB, Hong JS (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Neuropsychopharmacology 11:1123–1134

    Article  CAS  Google Scholar 

  9. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51–59

    Article  PubMed  CAS  Google Scholar 

  10. Kim HJ, Leeds P, Chuang DM (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 110:1226–1240

    Article  PubMed  CAS  Google Scholar 

  11. Desmet CJ, Peeper DS (2006) The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63:755–759

    Article  PubMed  CAS  Google Scholar 

  12. Schmidt AL, de Farias CB, Abujamra AL, Kapczinski F, Schwartsmann G, Brunetto AL, Roesler R (2010) BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J Mol Neurosci 40:303–310

    Article  PubMed  CAS  Google Scholar 

  13. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC (2004) Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10:1150–1159

    Article  PubMed  CAS  Google Scholar 

  14. Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O (2008) HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs 19:849–857

    Article  PubMed  CAS  Google Scholar 

  15. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL (2010) Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. CNS Neurol Disord Drug Targets 9:335–348

    PubMed  CAS  Google Scholar 

  16. dos Santos MP, Schwartsmann G, Roesler R, Brunetto AL, Abujamra AL (2009) Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk Res 33:218–221

    Article  PubMed  Google Scholar 

  17. He XM, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD (1989) Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48:48–68

    Article  PubMed  CAS  Google Scholar 

  18. Tamura K, Shimizu K, Yamada M, Okamoto Y, Matsui Y, Park KC, Mabuchi E, Moriuchi S, Mogami H (1989) Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. Cancer Res 49:5380–5384

    PubMed  CAS  Google Scholar 

  19. Zavarella S, Nakada M, Belverud S, Coniglio SJ, Chan A, Mittler MA, Schneider SJ, Symons M (2009) Role of Rac1-regulated signaling in medulloblastoma invasion. Laboratory investigation. J Neurosurg Pediatr 4:97–104

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the National Council for Scientific and Technological Development (CNPq; grant number 303703/2009-1 to R.R); the Rafael Koff Acordi Research Fund, Children’s Cancer Institute (ICI-RS); the National Institute for Translational Medicine (INCT-TM); and the South American Office for Anticancer Drug Development.

Ethical standards

All experimental procedures were approved by the institutional research ethics committee (GPPG-HCPA). The present study does not involve the use of experimental animals or materials obtained from patients.

Conflict of interest

The authors declare that they have no conflict of interest

Author information

Authors and Affiliations

  1. Cancer Research Laboratory, University Hospital Research Center (CPE-HCPA), Porto Alegre, RS, Brazil

    Carolina Nör, Caroline Brunetto de Farias, Ana Lucia Abujamra, Gilberto Schwartsmann, Algemir Lunardi Brunetto & Rafael Roesler

  2. Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil

    Carolina Nör, Caroline Brunetto de Farias, Ana Lucia Abujamra, Gilberto Schwartsmann, Algemir Lunardi Brunetto & Rafael Roesler

  3. National Institute for Translational Medicine (INCT-TM), 90035-003, Porto Alegre, RS, Brazil

    Carolina Nör, Caroline Brunetto de Farias, Ana Lucia Abujamra, Gilberto Schwartsmann, Algemir Lunardi Brunetto & Rafael Roesler

  4. Laboratory of Neuropharmacology and Neural Tumor Biology, Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul. Rua Sarmento Leite, 500 (ICBS, Campus Centro/UFRGS), 90050-170, Porto Alegre, RS, Brazil

    Carolina Nör, Caroline Brunetto de Farias & Rafael Roesler

  5. Children’s Cancer Institute (ICI-RS) and Pediatric Oncology Unit, University Hospital (HCPA), Federal University of Rio Grande do Sul, 90035-003, Porto Alegre, RS, Brazil

    Caroline Brunetto de Farias, Ana Lucia Abujamra & Algemir Lunardi Brunetto

  6. School of Medicine, Federal University of Rio Grande do Sul, 90035-003, Porto Alegre, RS, Brazil

    Gilberto Schwartsmann & Algemir Lunardi Brunetto

Authors
  1. Carolina Nör
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Brunetto de Farias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Lucia Abujamra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gilberto Schwartsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Algemir Lunardi Brunetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rafael Roesler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Roesler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nör, C., de Farias, C.B., Abujamra, A.L. et al. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Childs Nerv Syst 27, 897–901 (2011). https://doi.org/10.1007/s00381-011-1439-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-011-1439-4

Keywords

Search

Navigation